The Hemostatic Effect of Ankaferd Blood Stopper in Rat Bleeding Models with Antithrombotic Drug Therapy: An Experimental In Vivo Study
Abstract
Objective: Ankaferd blood stopper is a mixture of five medicinal plant extracts used as a hemostatic agent for management of external hemorrhage. The aim of this study was to evaluate the hemostatic effects of Ankaferd blood stopper (ABS) on bleeding after tooth extraction in vivo models with taking antithrombotic drug.
Materials and Methods: Forty-eight male Albino Wistar rats were divided into six groups of 8 animals each. Maxillary right first molar tooth of the rats were extracted under general anesthesia. 2 mL saline solutions were applied topically to Control group (group 1), Warfarin group (group 3) and Heparin group (group 5) on the sockets immediately after extraction. Two ml ABS’s were applied topically to Ankaferd group (group 2), Warfarin-Ankaferd group (group 4) and Heparin-Ankaferd group (group 6) likewise. The bleeding time and the amount of bleeding were compared among 6 groups just following the tooth extraction. The collected data results were analysed statistically by the ANOVA followed by Tukey test for pair-wise comparisons.
Results: The bleeding time was longer in Warfarin and Heparin group than the Control group (p<0.05), Ankaferd, Warfarin-Ankaferd and Heparin-Ankaferd groups (p>0.05). Similiarly, the amount of bleeding of Warfarin group was significantly higher than those of the Control and Warfarin-Ankaferd group (p<0.05). The amount of bleeding were lower in Control, Heparin and Heparin-Ankaferd groups but the differences were not statistically significant (p>0.05).
Conclusion: Topically administered ABS is less effective on bleeding control of Warfarin-induced bleeding model than Heparin-induced bleeding model in wistar rats. Resulting small difference in between warfarin and heparin should be investigated in future studies.
References
- 1. Iynen I, Sogut O, Kose R. The efficacy of Ankaferd Blood Stopper in heparin-induced hemostatic abnormality in a rat epistaxis model. Otolaryngol Head Neck Surg 2011; 145: 840-4.
- 2. Işler SC, Demircan S, Cakarer S, Cebi Z, Keskin C, Soluk M, et al. Effects of folk medicinal plant extract Ankaferd Blood Stopper on early bone healing. J Appl Oral Sci 2010; 18: 409-14.
- 3. Leblebisatan G, Bay A, Karakus SC, Kekilli M, Haznedaroglu IC. Topical Ankaferd hemostat application for the management of oral cavity bleedings in children with hemorrhagic diathesis. Blood Coagul Fibrinolysis 2012; 23: 494-7.
- 4. Tokgöz H, Karakaya K, Hanci V, Abduşoğlu M, Erol B, Türksoy O, et al. Protective value of a folkloric medicinal plant extract against mortality and hemorrhage in a life-threatening renal trauma model. Urology 2010; 75: 1515.e9-14.
- 5. Uçar Albayrak C, Caliskan U, Haznedaroglu IC, Goker H. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. J Int Med Res 2008; 36: 1447-8.
- 6. Kosar A, Tezel C, Orki A, Kiral H, Arman B. Bronchogenic cysts of the lung: report of 29 cases. Heart Lung Circ 2009; 18: 214-8.
- 7. Çakarer S, Eyüpoğlu E, Günes ÇÖ, Küseoğlu BG, Berberoğlu HK, Keskin C. Evaluation of the hemostatic effects of Ankaferd blood stopper during dental extractions in patients on antithrombotic therapy. Clin Appl Thromb Hemost 2013; 19: 96-9.
- 8. Uz B, Guven GS, Isik A, Kuyumcu ME, Bektas O, Eliacik E, et al. Long-term sustained hemorrhage due to bone marrow biopsy successfully treated with topical ankaferd hemostat in a bleeding-prone patient with secondary amyloidosis. Clin Appl Thromb Hemost 2013; 19: 338-40.
- 9. Huri E, Haznedaroglu IC, Akgul T, Astarci M, Ustun H, Germiyanoulu C. Biphasic effects of ankaferd blood stopper on renal tubular apoptosis in the rat partial nephrectomy model representing distinct levels of hemorrhage. Saudi Med J 2010; 31: 864-8.
- 10. Kalayci MU, Soylu A, Eroglu HE, Kubilay D, Sancak B, Ugurluoglu C, et al. Effect of ankaferd blood stopper on hemostasis and histopathological score in experimental liver injury. Bratisl Lek Listy 2010; 111: 183-8.
- 11. Kilic O, Gonen M, Acar K, Yurdakul T, Avunduk MC, Esen HH, et al. Haemostatic role and histopathological effects of a new haemostatic agent in a rat bladder haemorrhage model: an experimental trial. BJU Int 2010; 105: 1722-5.
- 12. Turhan N, Bilgili H, Captug O, Kurt M, Shorbagi A, Beyazit Y, et al. Evaluation of a haemostatic agent in rabbits. Afr J Tradit Complement Altern Med 2011; 8: 61-5.
- 13. Mihmanli A, Ulker Z, Alpsoy L, Ezirganli S. Evaluation of cytotoxicity of a new hemostatic agent Ankaferd Blood Stopper® using different assays. Hum Exp Toxicol 2012; 31: 780-7.
- 14. Cipil HS, Kosar A, Kaya A, Uz B, Haznedaroglu IC, Goker H, et al. In vivo hemostatic effect of the medicinal plant extract Ankaferd Blood Stopper in rats pretreated with warfarin. Clin Appl Thromb Hemost 2009; 15: 270-6.
- 15. Evans IL, Sayers MS, Gibbons AJ, Price G, Snooks H, Sugar AW. Can warfarin be continued during dental extraction? Results of a randomized controlled trial. Br J Oral Maxillofac Surg 2002; 40: 248-52.
- 16. Sacco R, Sacco M, Carpenedo M, Mannucci PM. Oral surgery in patients on oral anticoagulant therapy: a randomized comparison of different intensity targets. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: 18-21.
- 17. Meric Teker A, Korkut AY, Kahya V, Gedikli O. Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis. Eur Arch Otorhinolaryngol 2010; 267: 1377-81.
- 18. Kandemir O, Buyukates M, Kandemir NO, Aktunc E, Gul AE, Gul S, et al. Demonstration of the histopathological and immunohistochemical effects of a novel hemostatic agent, Ankaferd Blood Stopper, on vascular tissue in a rat aortic bleeding model. J Cardiothorac Surg 2010; 5: 110.
- 19. Altunhan H, Annagür A, Tokgöz H, Çaliskan Ü, Örs R. Persistent nasal bleeding due to nasal CPAP application in 2 premature newborns successfully treated with topical “Ankaferd blood stopper”. Clin Appl Thromb Hemost 2011; 17: E181-2.
- 20. Kosar A, Cipil HS, Kaya A, Uz B, Haznedaroglu IC, Goker H, et al. The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model. Blood Coagul Fibrinolysis 2009; 20: 185-90.
- 21. Bilgili H, Kosar A, Kurt M, Onal IK, Goker H, Captug O, et al. Hemostatic efficacy of Ankaferd Blood Stopper in a swine bleeding model. Med Princ Pract 2009; 18: 165-9.
- 22. Okumura LM, Negretto GW, Carvalho CG. Unusual Warfarin Dose To Achieve Therapeutic INR In a 4-Month Old Child: Non-Genetics Risk Factors Are Still A Challenge. Rev Paul Pediatr 2017; 35: 472-5.
- 23. Ruud E, Holmstrøm H, Bergan S, Wesenberg F. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. Pediatr Blood Cancer 2008; 50: 710-3.
Details
| Primary Language | English |
|---|---|
| Subjects | Cardiovascular Surgery, Dentistry (Other) |
| Journal Section | Research Article |
| Authors | |
| Publication Date | December 31, 2018 |
| Published in Issue | Year 2018 Volume: 19 Issue: 4 |